AccessibilityHelp

Traws Pharma(NASDAQ) ONTX

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2013)-100%
5 Year-100%
1 Year-87%
1 Month-39%
N/A
Traws Pharma last closing stock price
MetricPriceDate
Last closeUSD 0.342026-10-26
Traws Pharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-6.93%USD 0.372026-10-19
1 month-39.44%USD 0.562026-09-25
3 month-33.51%USD 0.512026-07-28
Year to date-69.81%USD 1.132025-12-31
1 year-87.41%USD 2.712025-10-24
3 year-97.8%USD 15.502023-10-27
5 year-99.6%USD 84.252021-10-27
Since inception-100%USD 1,118,248.602013-07-25

Traws Pharma Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$21.57

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

N/A

ONTX News

Foolcom-Featured.png

Traws Pharma Posts Q2 Revenue Jump

Motley Fool Markets TeamAug 14, 2025
Growth - GettyImages-905948482

Why Onconova Therapeutics Stock Soared Today

Joe TenebrusoFeb 17, 2021

This Week in Biotech: Buyouts, an FDA Approval, and Clinical Data. Oh, My!

Sean WilliamsFeb 22, 2014

3 Horrendous Health-Care Stocks This Week

Keith SpeightsFeb 22, 2014

Why Onconova Therapeutics Inc. Shares Imploded

Sean WilliamsFeb 20, 2014

Why Jabil Circuit, Inc., Onconova Therapeutics Inc., and Gogo Inc. Plunged Today

Dan CaplingerDec 18, 2013

Why Onconova Therapeutics Inc. Shares Crashed

Sean WilliamsDec 18, 2013

Keep an Eye on Onconova, Enzymotec, DepoMed, and Omeros Today

Leo SunDec 18, 2013

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Traws Pharma

Traws Pharma, Inc. is a biopharmaceutical company focused on developing innovative small-molecule medications for respiratory viral infections and various cancers. The company is advancing a promising pipeline that includes treatments for COVID-19 and influenza, as well as oncology therapies.

Products and Services
  • TRX01 (travatrelvir) for COVID-19 treatment
  • TRX100 (viroxavir) targeting pandemic influenza
  • Oncology portfolio featuring narazaciclib for cancer therapy
Growth Outlook
  • Recent clinical trials show potential for TRX01 and TRX100 to address unmet medical needs
  • Expansion into oncology with narazaciclib in Phase 1/2 trials
  • Strong cash position with $3.13 million available as of March 2026
Financial Highlights
  • Quarterly net income of -$3.05 million reported for Q2 2026
  • Trailing twelve months (TTM) revenue of $2.73 million in Q2 2025
  • Cash and cash equivalents of $3.13 million as of March 2026
Traws Pharma, Inc. is positioned in the biotechnology sector, focusing on critical areas of healthcare. The company’s innovative approach to drug development aims to address significant health challenges, particularly in the context of viral infections and cancer treatment. The ongoing clinical trials and the development of novel therapies highlight the potential for future growth and market impact. Recent financial data indicates a commitment to research and development, with substantial investments aimed at advancing the company's pipeline. The current cash reserves provide a foundation for continued operations and development efforts.
AI Generated • Oct 17, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

7

CEO

Iain David Dukes, PhD

Website

www.trawspharma.com

Headquarters

San Francisco, CA 9410, US

ONTX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

-293.50%

Net Income Margin

-0.58%

Return on Equity

-0.53%

Return on Capital

N/A

Return on Assets

-199.36%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Traws Pharma Performance Analysis

Traws Pharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 226,0000.0%
20232023-12-31USD 226,0000.0%
20242024-12-31USD 226,0000.0%
20252025-12-31USD 2,790,0001134.5%
Traws Pharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -22.68-5.5%
20232023-12-31USD -22.57-0.5%
20242024-12-31USD -106.70372.8%
20252025-12-31USD 1.09N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

+0.0%

Gross Profit

-$0.04

-0.0%

Gross Margin

99.96%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.29

N/A

Employees

7

N/A

Net Income

-$3.05

+3.3%

EBITDA

-$3.13

+2.5%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$5.02

-61.7%

Total Debt

$0.00

N/A

Accounts Receivable

$3.45

+2.6%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-159.21%

+1.5%

Return on Invested Capital

-242.20%

+2.4%

Free Cash Flow

-$7.50

+1.3%

Operating Cash Flow

-$7.50

+1.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CDIOCardio Diagnostics Holdings, Inc.
$1.72+1.78%
CTRMCastor Maritime Inc.
$1.57-1.88%
GRCEGrace Therapeutics, Inc.
$1.81-6.22%
IBIOiBio, Inc.
$0.71-1.50%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$12.59-16.95%
EWZiShares - iShares Msci Brazil ETF
$34.15-19.82%
ITUBItaú Unibanco
$7.70-20.37%
XPXP
$15.71-48.36%

Questions About ONTX

What is the current price of Traws Pharma?

Traws Pharma is trading at N/A per share.

What is the 52-week range for Traws Pharma?

Over the past 52 weeks, Traws Pharma has traded between N/A and N/A.

How much debt does Traws Pharma have?

As of the most recent reporting period, Traws Pharma reported total debt of $0.00.

How much cash does Traws Pharma have on hand?

Traws Pharma reported $5.02M in cash and cash equivalents in its most recent financial results.

What is Traws Pharma’s dividend yield?

Traws Pharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services